Details for Patent: 8,869,794

« Back to Dashboard

Which drugs does patent 8,869,794 protect, and when does it expire?

Patent 8,869,794 protects TOBI PODHALER and is included in one NDA.

Summary for Patent: 8,869,794

Title:	Aerosolization apparatus with capsule puncturing member
Abstract:	An aerosolization apparatus comprises a housing defining a chamber having one or more air inlets. The chamber is sized to receive a capsule which contains an aerosolizable pharmaceutical formulation. A puncturing mechanism is provided within the housing and comprising a puncture member. The puncture member comprises a forward end shaped to form a cutting edge that is effective in cutting the wall of the capsule to create an opening into the capsule. The puncture member also comprises a trailing end shaped so that it has a non-cutting surface that does not cut the wall of the capsule when the trailing end is inserted into the opening created by the forward end. An end section is associated with the housing. The end section is sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to inhale aerosolized pharmaceutical formulation that has exited the capsule through the opening created in the capsule.
Inventor(s):	Jon David Tuckwell, Thomas Christopher St. Quintin
Assignee:	BGP Products Operations GmbH
Application Number:	US10/821,652
Patent Claim Types: see list of patent claims	Use; Formulation; Device; Dosage form;

US Patent 8,869,794: Claim Scope, Expiration, Litigation Risk and Capsule-Inhaler Patent Landscape

US Patent No. 8,869,794 protects a capsule-based aerosolization device and, more narrowly, a non-pointed puncture member made from round wire. Its commercial significance is concentrated in the geometry of the puncture tip: a cutting forward edge creates the capsule opening, while a trailing planar or straight edge enters the opening without cutting a second portion of the capsule wall.

The patent does not claim a specific active pharmaceutical ingredient, powder composition, capsule material, or therapeutic indication. Its principal value is as a device patent that may read on dry-powder inhalers using pierced capsules.

What does US Patent 8,869,794 cover?

The patent covers three related categories:

1. An aerosolization apparatus containing:

   • A housing and capsule chamber.
   • One or more air inlets.
   • A puncture member formed from round wire.
   • A mouthpiece or nasal end section.
   • A capsule containing an aerosolizable pharmaceutical formulation.

2. Methods of using the puncture member to open a capsule, aerosolize the formulation, and administer it through inhalation.

3. The puncture member itself, independent of the complete inhaler.

The central technical limitation is a two-function puncture tip. The forward portion cuts the capsule wall. The trailing portion is deliberately non-cutting and remains outside, or enters the existing opening without cutting additional capsule material.

How many independent claims does US 8,869,794 have?

The patent has seven independent claims:

Claim	Category	Principal subject matter
1	Apparatus	Capsule inhaler with round-wire puncture member, cutting forward end and angled trailing portion
9	Apparatus	Curved cutting end, straight non-cutting trailing edge and angled planar surface
11	Apparatus	Non-pointed forward end, straight opposite edge and planar intermediate portion
12	Apparatus	D-shaped tip formed from a round wire by an angular planar cut
13	Apparatus	Generally U-shaped puncture member with D-shaped tip
14	Method	Puncturing, aerosolizing and administering a capsule formulation
16	Method	Method using curved forward end and non-cutting straight trailing edge
17	Method	Method using a generally circular tip, D-shaped surface and angled planar portion
18	Component	Puncture member for a puncturable container

The numbering produces eight independent claims rather than seven because claims 1, 9, 11, 12, 13, 14, 16, 17 and 18 are all independent. Claims 2 through 8, 10 and 15 are dependent.

What are the key limitations in independent claim 1?

Claim 1 requires the combination of several limitations:

1. A housing defining a chamber.
2. One or more air inlets.
3. A chamber sized to receive a capsule.
4. A capsule containing an aerosolizable pharmaceutical formulation.
5. A puncturing mechanism inside the housing.
6. A puncture member made from round wire.
7. A forward cutting edge capable of cutting the capsule wall.
8. A trailing end with an angled planar portion.
9. The angled planar portion must be insertable into the opening.
10. The rearward end must remain outside the capsule when fully inserted and must not cut another wall portion.
11. An end section configured for oral or nasal inhalation.

The claim is not satisfied merely by an inhaler with a sharp needle. A competing device would need to meet the structural and functional requirements relating to the round wire, angled planar portion and non-cutting trailing end.

The phrase "remains outside of the capsule" creates a particularly important limitation. It distinguishes the claimed structure from a needle that passes entirely through the capsule or cuts both sides of the capsule wall.

What do claims 9, 11, 12 and 13 add?

Claim 9: curved cutting end and tangent relationship

Claim 9 narrows the tip geometry by requiring:

• A curved forward end.
• A straight trailing edge.
• A straight edge generally parallel to a tangent at the midpoint of the curved forward end.
• An angled planar surface between the forward and trailing portions.
• A non-cutting trailing surface.

The tangent limitation is a high-specificity structural limitation. It may make literal infringement more difficult to establish against a device using a different angular relationship, even if the device has a curved cutting edge.

Claim 11: non-pointed forward end

Claim 11 expressly requires that the forward end is not pointed. The claim therefore excludes conventional pointed needles if the accused structure has a true point rather than a planar or otherwise non-pointed cutting edge.

The claim also requires a straight edge opposite the cutting edge and a planar portion between them.

Claim 12: D-shaped cross-section

Claim 12 requires:

• A round wire with a circular cross-section before modification.
• Forward and trailing ends formed by an angular planar cut.
• A flat planar surface generally parallel to a tangent at the midpoint of the curved forward end.
• A generally D-shaped tip cross-section.

This claim is directed to the manufacturing result of cutting or reshaping round wire. The D-shaped geometry is a meaningful design constraint and may provide a strong non-infringement route for devices using a triangular, conical, rectangular or conventional blade profile.

Claim 13: U-shaped puncture member

Claim 13 requires a generally U-shaped puncture member with a generally circular cross-section. It also requires a straight trailing edge, a non-pointed forward end, an angled planar surface and a D-shaped surface.

This claim may be relevant to devices using paired arms or a U-shaped wire element rather than a single isolated puncture pin.

What do dependent claims 2 through 8 protect?

Claim	Added limitation
2	Removable end section providing access to the chamber
3	Pair of puncture members
4	Puncture of only one end of the capsule
5	Chamber and capsule longitudinal axes form an angle below approximately 45 degrees
6	Capsule received lengthwise in an elongated chamber
7	Chamber width is less than capsule length
8	Inlet creates swirling airflow

Claims 3, 5, 7 and 8 are commercially relevant because they combine puncture geometry with airflow and capsule-positioning features.

Claim 8 is the principal airflow claim. It does not require a specific number, shape or orientation of inlets, but it requires that the inlet arrangement create a swirling airflow within the chamber. A device using straight-through airflow may avoid literal infringement of claim 8 while still potentially implicating the independent apparatus claims.

What do the method claims cover?

Claims 14, 16 and 17 cover a sequence rather than only a device structure:

1. Providing a capsule with an aerosolizable formulation.
2. Advancing the puncture member through the capsule wall.
3. Creating an opening.
4. Flowing air through the chamber to aerosolize the formulation.
5. Administering the formulation to the respiratory tract during inhalation.

The method claims require use of the specified puncture-member geometry. They do not identify a particular active ingredient, particle size, excipient, disease or dosage.

A manufacturer may face lower method-claim exposure if its device is sold without instructions directing the claimed sequence, although inducement and contributory-infringement analysis depends on the product labeling, user instructions and the underlying device configuration.

What does claim 18 protect independently?

Claim 18 is a component claim directed to the puncture member itself. It does not require:

• An inhaler housing.
• An air inlet.
• A capsule chamber.
• A mouthpiece.
• A pharmaceutical formulation.

It requires a generally round wire material with:

• An angled planar surface.
• A curved forward end forming a cutting edge.
• A trailing end with a straight, non-cutting edge.
• A flat surface generally parallel to a tangent at the midpoint of the curved forward end.
• A generally D-shaped cross-section.

Claim 18 creates the clearest potential exposure for a component supplier. A supplier could face direct infringement issues if it makes or sells a puncture member meeting the claim, even if the component is later incorporated into a third-party inhaler.

What is the practical scope of the patent?

The patent has a narrow but technically focused scope.

Covered design profile

The strongest literal-infringement case generally would involve a capsule inhaler having:

• A capsule chamber.
• A round-wire puncture element.
• A non-pointed or curved cutting edge.
• An angled planar transition.
• A straight or flat trailing edge.
• A D-shaped puncture-tip cross-section.
• A mouthpiece or nasal delivery section.

Likely non-infringing design alternatives

Potential design-arounds include:

• A conventional pointed needle.
• A flat blade that cuts the capsule without a round-wire origin.
• A puncture tip with a pointed trailing end.
• A puncture element that cuts both capsule walls.
• A cutter with no angled planar portion.
• A rectangular or triangular cross-section.
• A device that uses a pre-opened capsule or peelable capsule.
• A device in which the capsule is not punctured.
• A nebulizer, soft-mist inhaler or metered-dose inhaler that does not use a capsule.
• A capsule chamber with airflow that does not produce swirling flow.

These alternatives may avoid literal infringement, but equivalence analysis would depend on claim construction, prosecution history and the specific geometry of the accused product. The non-pointed forward end and D-shaped surface limitations could also restrict the patent owner’s ability to invoke the doctrine of equivalents if those limitations were added to overcome prior art.

What is the patent’s likely expiration date?

US Patent No. 8,869,794 issued on October 28, 2014. The ordinary US patent term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and any applicable patent-term extension under 35 U.S.C. §§ 154 and 156.[1]

The issue date alone does not establish the expiration date. The controlling record must be taken from:

• The patent’s earliest effective nonprovisional priority.
• Continuation or divisional relationships.
• Patent-term adjustment.
• Any terminal disclaimer.
• Any patent-term extension.

Because the patent claims an inhaler apparatus rather than a drug active ingredient, Hatch-Waxman patent-term extension for an approved drug is not automatically available. A device patent generally does not obtain the same Orange Book-linked exclusivity treatment as a patent claiming an approved active ingredient, formulation or method of use.

What is the Orange Book status of US 8,869,794?

The claims provided are directed to an aerosolization apparatus, puncture member and inhalation method. They do not claim:

• A named active ingredient.
• A pharmaceutical composition.
• A drug formulation by chemical or quantitative composition.
• A labeled indication.

On that basis, the patent is not a conventional Orange Book drug patent. FDA Orange Book listing is generally tied to patents submitted by an approved new drug application holder that claim the drug substance, drug product or an approved method of use.[2]

A device patent can still have commercial importance if the device is supplied with an approved drug product or is part of a drug-device combination. Orange Book relevance would depend on whether the NDA holder submitted the patent, whether FDA accepted it for publication, and whether the listed claims meet the statutory listing categories.

The patent should therefore be treated primarily as a device patent, not as a standalone chemical exclusivity right.

Does the patent create Paragraph IV risk?

A Paragraph IV certification is relevant when an ANDA applicant challenges an Orange Book-listed patent. The patent’s apparatus-focused claims do not, by themselves, establish a conventional Paragraph IV barrier to a generic drug application.

Risk may arise indirectly where:

• The approved product is supplied only in a patented capsule inhaler.
• The patent is listed in the Orange Book against the product NDA.
• The ANDA applicant seeks approval for the same device or a device that practices the listed claims.
• The product is regulated as a drug-device combination with a referenced delivery system.

The existence of US 8,869,794 alone does not show that an ANDA applicant faces a four-year or 30-month stay. Those consequences depend on FDA listing, the NDA holder’s patent submission and the ANDA applicant’s certification.

What patent litigation affects US 8,869,794?

The supplied information does not establish a litigation history, asserted claims, claim-construction rulings or settlement agreement involving this patent. A reliable litigation assessment requires the patent’s assignment record, PACER filings, district-court dockets and PTAB records.

The key litigation questions are:

Issue	Relevance
Claim construction	Meaning of “round wire,” “D-shaped,” “angled planar portion,” “non-cutting surface” and “generally parallel”
Anticipation	Earlier capsule inhalers with non-pointed cutters
Obviousness	Combination of known capsule-puncturing structures with known airflow chambers
Written description	Support for the multiple tip geometries and D-shaped cross-section
Enablement	Ability to make and use the claimed puncture members across the claim breadth
Indefiniteness	Scope of “generally,” “about,” “curved,” “straight” and “sized and shaped”
Prosecution history	Whether geometry limitations were added to distinguish prior art
Equivalents	Whether amended structural limitations restrict expansion under the doctrine of equivalents

The repeated geometry limitations across independent claims suggest that claim scope is likely to turn on precise construction of the puncture-tip structure rather than on the general concept of capsule inhalation.

How strong is the patent estate?

The patent is strongest against products that copy the specific puncture-member geometry. It is weaker as a platform patent against the broader capsule-inhaler market.

Strength factor	Assessment
Device-specific protection	Strong
Active-ingredient protection	None shown
Formulation protection	None shown
Capsule-inhaler coverage	Moderate, limited by tip geometry
Component-supplier exposure	Significant under claim 18
Generic drug blocking power	Limited unless Orange Book-listed
Design-around difficulty	Moderate to low
Prior-art vulnerability	Dependent on earlier capsule-puncture mechanisms
Method-claim value	Secondary to apparatus and component claims
Biosimilar relevance	Minimal

The patent does not protect a biologic, biosimilar, active pharmaceutical ingredient or therapeutic indication. Biosimilar litigation is therefore not a material risk category for this patent. The relevant competition is among capsule-based inhalers, dry-powder delivery systems and device suppliers.

How does US 8,869,794 compare with competing inhaler patent estates?

Technology	Typical protected subject matter	Relationship to US 8,869,794
Capsule-based dry-powder inhaler	Capsule chamber, airflow path, piercing mechanism and dose delivery	Most relevant technology class
Blister-based dry-powder inhaler	Foil blister opening and dose indexing	Usually outside the capsule-puncture claims
Metered-dose inhaler	Canister valve, actuator and propellant formulation	Generally outside the patent
Soft-mist inhaler	Mechanical energy source and nozzle system	Generally outside the patent
Nebulizer	Liquid reservoir, aerosol generator and fluid path	Generally outside the patent
Device containing pointed needles	Conventional capsule piercing	May avoid claims requiring non-pointed or D-shaped tip geometry
Device using cutting blades	Potentially outside claims requiring round wire	Depends on whether the blade is structurally derived from round wire

The patent is therefore a subcomponent patent within the broader dry-powder inhaler landscape. It does not create a monopoly over capsule inhalation.

What manufacturing and licensing barriers does the patent create?

The manufacturing barrier is concentrated in the puncture member. A supplier must control:

• Wire diameter and circularity.
• The angular cutting operation.
• The curved forward edge.
• The planar transition.
• The straight trailing edge.
• The D-shaped tip profile.
• Consistent orientation and attachment within the housing.

Quality-control records may become important in litigation because small dimensional variations could determine whether the manufactured part falls within the claims.

A licensing program would likely be structured around one of three assets:

1. The complete inhaler.
2. A replacement or OEM puncture assembly.
3. A drug-device combination using a capsule formulation.

A license limited to the puncture member may be commercially efficient for device manufacturers but insufficient for a company that also needs freedom to operate under separate patents covering the chamber, airflow path, capsule formulation, dose metering, mouthpiece or therapeutic product.

What generic and launch scenarios are most plausible?

Scenario 1: Same device, same capsule format

This presents the highest infringement risk. The risk increases if the competitor uses a round-wire, curved or non-pointed D-shaped cutter.

Scenario 2: Same drug, redesigned puncture member

This is the most direct design-around path. A competitor could use a pointed needle, a blade, a different cross-section or a cutter that does not include the claimed trailing geometry.

Scenario 3: Same drug, different delivery platform

A blister inhaler, metered-dose inhaler or soft-mist system would generally avoid the apparatus claims if it does not use a punctured capsule.

Scenario 4: Device-only competition

A component or device supplier could face claim 18 exposure even if the pharmaceutical company changes the formulation. The patent’s component claim separates the puncture-member risk from the drug product itself.

Scenario 5: Authorized generic or licensed launch

A settlement or license could permit use of the patented geometry while leaving separate patents covering the active ingredient, formulation or indication intact. The commercial value of the license would depend on the remaining product-specific patent estate.

What should an FTO review examine?

A complete freedom-to-operate review should separate the following patent groups:

1. Puncture-member patents.
2. Capsule-chamber and airflow patents.
3. Mouthpiece and nasal-delivery patents.
4. Capsule and powder-formulation patents.
5. Dose-metering and capsule-positioning patents.
6. Active-ingredient patents.
7. Method-of-use patents.
8. Manufacturing-process patents.
9. Foreign counterparts.
10. Continuations and divisionals with broader or differently drafted claims.

US 8,869,794 should not be treated as the entire inhaler patent estate. A product may avoid this patent and still infringe patents covering the capsule, airflow path, device actuation, formulation or labeled use.

Key Takeaways

• US 8,869,794 is primarily a device and component patent.
• Its core invention is a round-wire puncture member with a cutting forward edge and non-cutting trailing geometry.
• Claims 1, 9, 11, 12 and 13 protect different structural versions of the puncture tip.
• Claims 14, 16 and 17 cover methods of puncturing, aerosolizing and administering a capsule formulation.
• Claim 18 creates standalone risk for suppliers of the puncture member.
• The patent does not claim an active pharmaceutical ingredient, drug composition or therapeutic indication.
• It is not inherently an Orange Book patent and does not automatically create Paragraph IV or 30-month-stay consequences.
• Its commercial strength depends on whether a competing capsule inhaler uses the claimed round-wire and D-shaped tip geometry.
• Pointed needles, non-round blades, alternative cross-sections and non-capsule delivery systems are principal design-around routes.
• Expiration must be calculated from the earliest effective nonprovisional filing date, adjusted for patent-term adjustment and any terminal disclaimer.

FAQs

Does US 8,869,794 cover the drug powder inside the capsule?

No. The claims cover the aerosolization apparatus, puncture member and inhalation method. They do not claim a specific active ingredient or powder formulation.

Can a competitor use a pointed needle without infringing the patent?

A pointed needle may avoid claims that expressly require a non-pointed forward end or a D-shaped tip. It may still require analysis against broader claims and other patents in the device estate.

Is claim 18 important for inhaler manufacturers?

Yes. Claim 18 is directed to the puncture member as a standalone component. It can create exposure for a component manufacturer even when the complete inhaler is assembled by another company.

Does the patent cover blister-pack inhalers?

Generally, no. The claims require a capsule-containing chamber and a puncture member that opens the capsule. Blister systems use a different dose-container architecture.

Can this patent block a generic drug launch?

Only indirectly, and only if the generic product uses a device that practices the claims or the patent is properly listed against the relevant approved drug product. The patent number alone does not establish a Hatch-Waxman blocking position.

References

1. United States Code. (2024). 35 U.S.C. §§ 154, 156. Patent term and patent term extension provisions.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
3. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,869,794, aerosolization apparatus, methods and puncture member.
4. U.S. Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, §§ 2111, 2112, 2113 and 2181. Claim construction and infringement-related examination principles.

Drugs Protected by US Patent 8,869,794

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Viatris	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013		RX	Yes	Yes	8,869,794		Y			TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA